The US Food and Drug Administration (FDA) recently approved a new, simplified formulation of Novartis’ Exjade (deferasirox) for the treatment of chronic iron overload. The company said that the agency approved its Jadenu (deferasirox) tablets for oral suspension for the treatment of chronic iron overload due to blood transfusions in …